65.80
Henry Schein Inc. stock is currently priced at $65.80, with a 24-hour trading volume of 722.61K.
It has seen a -0.71% decreased in the last 24 hours and a -9.58% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $65.94 pivot point. If it approaches the $65.37 support level, significant changes may occur.
Previous Close:
$66.27
Open:
$65.79
24h Volume:
722.61K
Market Cap:
$8.43B
Revenue:
$12.45B
Net Income/Loss:
$388.00M
P/E Ratio:
19.24
EPS:
3.42
Net Cash Flow:
$473.00M
1W Performance:
-3.96%
1M Performance:
-9.58%
6M Performance:
-12.57%
1Y Performance:
-12.04%
Henry Schein Inc. Stock (HSIC) Company Profile
Name
Henry Schein Inc.
Sector
Industry
Phone
631-843-5500
Address
135 Duryea Road, Melville, NY
Henry Schein Inc. Stock (HSIC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
Nov-10-23 | Upgrade | Stifel | Hold → Buy |
Aug-08-22 | Upgrade | UBS | Sell → Neutral |
Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-13-22 | Resumed | Credit Suisse | Outperform |
Jan-31-22 | Initiated | Morgan Stanley | Underweight |
Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
Oct-01-21 | Resumed | Credit Suisse | Neutral |
Feb-08-21 | Resumed | Piper Sandler | Overweight |
Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
May-30-19 | Initiated | Wolfe Research | Underperform |
May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Apr-18-19 | Initiated | Guggenheim | Buy |
Jan-17-19 | Initiated | UBS | Sell |
Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
Nov-08-18 | Reiterated | Barrington Research | Outperform |
Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
Oct-19-18 | Resumed | Goldman | Neutral |
Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
Aug-07-18 | Reiterated | Stifel | Hold |
Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc. Stock (HSIC) Latest News
4 Stocks to Buy Amid Dental Supplies Industry Challenges
Zacks Investment Research
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
Zacks Investment Research
Why Earnings Season Could Be Great for Henry Schein (HSIC) - Yahoo Singapore News
Yahoo Singapore News
Henry Schein Inc. stock outperforms competitors despite losses on the day - MarketWatch
MarketWatch
Henry Schein Inc. [HSIC] Sr. VP & Chief Legal Officer makes an insider purchase of 4134 shares worth 0.29 million ... - Knox Daily
Knox Daily
Henry Schein (HSIC) Expands Data Analytics to Private Practices - Yahoo Movies Canada
Yahoo Movies Canada
Henry Schein Inc. Stock (HSIC) Financials Data
Henry Schein Inc. (HSIC) Revenue 2024
HSIC reported a revenue (TTM) of $12.45 billion for the quarter ending March 31, 2024, a -0.61% decline year-over-year.
Henry Schein Inc. (HSIC) Net Income 2024
HSIC net income (TTM) was $388.00 million for the quarter ending March 31, 2024, a -18.83% decrease year-over-year.
Henry Schein Inc. (HSIC) Cash Flow 2024
HSIC recorded a free cash flow (TTM) of $473.00 million for the quarter ending March 31, 2024, a +22.22% increase year-over-year.
Henry Schein Inc. (HSIC) Earnings per Share 2024
HSIC earnings per share (TTM) was $2.97 for the quarter ending March 31, 2024, a -15.62% decline year-over-year.
About Henry Schein Inc.
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.
Cap:
|
Volume (24h):